303 results about "Treatment outcome" patented technology

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

A method useful for facilitating choosing a treatment or treatment regime and for predicting the outcome of a treatment for a disorder which is diagnosed and monitored by a physician or other appropriately trained and licensed professional, such as for example, a psychologist, based upon the symptoms experienced by a patient. Unipolar depression is an example of such a disorder, however the model may find use with other disorders and conditions wherein the patient response to treatment is variable. In the preferred embodiment, the method for predicting patient response includes the steps of performing at least one measurement of a symptom on a patient and measuring that symptom so as to derive a baseline patient profile, such as for example, determining the symptom profile with time; defining a set of a plurality of predictor variables which define the data of the baseline patient profile, wherein the set of predictor variables includes predictive symptoms and a set of treatment options; deriving a model that represents the relationship between patient response and the set of predictor variables; and utilizing the model to predict the response of said patient to a treatment. A neural net architecture is utilized to define a non-linear, second order model which is utilized to analyze the patient data and generate the predictive database from entered patient data.

The invention relates to planning orthodontic treatment for a patient, including surgery, using biological constrains such as those arising from bone, soft tissue, and roots of patient's teeth. The invention disclosed herein provides capability to vary the movement ratio between the teeth and bone and soft tissue through treatment simulation to assess the risk factor associated with a particular treatment plan. The invention further provides capability to monitor results of the treatment to determine the actual movement ratio between the teeth and bone and soft tissue and update the database. Additionally, a method and apparatus are disclosed enabling an orthodontist or a user to create an unified three dimensional virtual craniofacial and dentition model of actual, as-is static and functional anatomy of a patient, from data representing facial bone structure; upper jaw and lower jaw; facial soft tissue; teeth including crowns and roots; information of the position of the roots relative to each other; and relative to the facial bone structure of the patient; obtained by scanning as-is anatomy of craniofacial and dentition structures of the patient with a volume scanning device; and data representing three dimensional virtual models of the patient's upper and lower gingiva, obtained from scanning the patient's upper and lower gingiva either (a) with a volume scanning device, or (a) with a surface scanning device. Such craniofacial and dentition models of the patient can be used in optimally planning treatment of a patient.

Novel modalities are introduced to treat joint and cartilage ischemia and related pathologies to improve outcome in the treatment of arthropathies and spondylopathies. The invention includes compositions, materials or devices which will improve oxygen, substrate and nutrient delivery to joint tissues and modalities to decrease the degradation of joint tissues by inflammatory and other destructive processes.

A method and system for patient-specific planning of cardiac therapy, such as cardiac resynchronization therapy (CRT), based on preoperative clinical data and medical images, such as ECG data, magnetic resonance imaging (MRI) data, and ultrasound data, is disclosed. A patient-specific anatomical model of the left and right ventricles is generated from medical image data of a patient. A patient-specific computational heart model, which comprises cardiac electrophysiology, biomechanics and hemodynamics, is generated based on the patient-specific anatomical model of the left and right ventricles and clinical data. Simulations of cardiac therapies, such as CRT at one or more anatomical locations are performed using the patient-specific computational heart model. Changes in clinical cardiac parameters are then computed from the patient-specific model, constituting predictors of therapy outcome useful for therapy planning and optimization.

Devices, systems, and methods for treating a heart of a patient may make use of structures which limit a size of a chamber of the heart, such as by deploying a tensile member to bring a wall of the heart toward (optionally into contact with) a septum of the heart. The implant may include an electrode or other structure for applying pacing signals to one or both ventricles of the heart, for defibrillating the heart, for sensing beating of the heart or the like. A wireless telemetry and control system may allowing the implant to treat congestive heart failure, monitor the results of the treatment, and apply appropriate electrical stimulation.

Methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. This prediction model can be used to accurately predict the intrinsic subtype of a subject diagnosed with or suspected of having breast cancer. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles, including microarrays and quantitative polymerase chain reaction assays, as well as kits comprising reagents for practicing the methods of the invention.

A medical treatment planning system includes a computer including a processor and memory, data stored in the memory, said data including a priori of information relating to medical conditions, medical treatments and treatment results, and treatment planning logic stored in the memory and executable by the processor. The treatment planning logic includes logic that obtains pre-treatment patient data describing the patient's medical condition, logic that analyzes the pre-treatment patient data relative to the a priori of information and, based on the analysis, formulates a first treatment plan for treating the patient, and logic that outputs the first treatment plan for evaluation by medical personnel.

A system and method for providing a predictive outcome in the form of a predictive best instruction for a therapeutic ophthalmic correction of a patient's vision defects. The predictive best instruction is derived from prospective therapeutic-outcome-influencing, new information that is analyzed in conjunction with optimized, historical therapeutic-outcome information. The instruction is preferably an optimized, custom, photoablative algorithm for driving a photoablative, excimer laser. The instruction can be provided on a fee basis.

A Computer program for determining a working profile for controlling a radiation system in refractive eye surgery, said program comprising:a user interface for input of data by a user; a data receiving interface for receiving measured data regarding the eye to be corrected; a working profile generator for generating a working profile on the basis of the input data and measured data; a generator for generating control data for controlling electromagnetic radiation; a simulator for simulating a treatment result on the basis of said control data for controlling the electromagnetic radiation and the effect of said radiation on eye tissue; a judgment stage for judging said treatment results by applying pre-given criteria; an iteration loop for generating iteratively, in case of a negative judgment, another amended profile on the basis of other data or for generating iteratively other control data for controlling the electromagnetic radiation; and a transfer means for transferring control data to a control of the radiation system in case of a positive judgment in the judgment stage.

The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.

A method of computer aided treatment planning is performed by generating and manipulating a three dimensional (3D) image of a region which includes at least one anatomical structure for which treatment, such as surgery, biopsy, tissue component analysis, prosthesis implantation, radiation, chemotherapy and the like, is contemplated. A virtual intervention, which simulates at least a portion of the contemplated treatment, is performed in the 3D image. The user can then determine the effect of the intervention and interactively modify the intervention for improved treatment results. Preferably, a warning is automatically provided if the intervention poses a risk of detrimental effect. The user can navigate through the contemplated region in the 3D image and assess the results. The treatment plans can be saved for comparison and post treatment evaluation.

Novel systems and methods for performing treatment (e.g., coloration) of keratinous fibers are disclosed. The methods and systems utilize one or more of a dispensing device which is configured to provide customized composition for treating keratinous fibers (e.g., a coloring composition), optionally formed from tablets; an optical reader, for obtaining sufficient characteristics of the keratinous fibers to make a realistic prediction of the outcome of a treatment (e.g., coloring treatment); a computational units for predicting an outcome of a treatment, optionally being interfaced with the dispensing device and for selecting a customized treatment; and tablet formulations which are useful in preparing customized composition for treating keratinous fibers. Further disclosed are rapidly disintegrating tablets for use in the preparation of compositions for treating keratinous fibers.

This invention relates to computer systems for conducting drug and biomarker discovery, drug development, and personalized medicine, and more generally managing healthcare, and in particular to a system and method for predicting the therapeutic value of a treatment to an individual. The treatment is associated with a function that describes, in a population of individuals, the benefit from a treatment, generally in terms of occurrence of a medical event under treatment, as a function of the risk (e.g., the occurrence of the medical event) without said treatment.

Appropriate assessment of wound oxygenation is critical to establish a diagnosis, to monitor the effect of the treatment, to guide the therapeutic process, to identify the presence of infection, and to predict the treatment outcome. Embodied systems and methods represent an enabling technology for noninvasive and objective assessment of wound tissue oxygenation. In addition to wound healing, disclosed embodiments offer low cost and portable avenues for noninvasive assessment of multiple clinical parameters for the detection and intervention of various malignancies in multiple soft tissue systems.

Present invention relates to a novel pharmaceutical composition containing an active ingredient(s) which is retained in the stomach or upper part of gastrointestinal tract for controlled delivery of medicament for improved local treatment, and / or better absorption from upper parts of gastrointestinal tract for effective therapeutic results. Present invention also provides a method for preparation of the said dosage form preferably in the form of a bilayer tablet, in which one layer constitutes for spatial control and the other being for temporal control.

The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprise determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response.

Physiological imaging-defined subvolumes of tissues / disease are identified to yield spatially-defined prognostic and / or predictive indicators and / or focal therapy targets within such tissues, in particular tumors, for evaluation over time, for example, prior to and after a therapy treatment. Medical image data is analyzed to delineate subvolumes of tissue based upon multiple physiological, metabolic, and biological imaging properties, where those subvolumes are extracted and analyzed in a probabilistic manner to associate with one or more abnormal or disease phenotype conditions.

This invention relates to a composition and method for treating diseases and disorders of the prostate such as prostatitis, benign prostatic hypertrophy, and prostate carcinoma. The prostate is treated by intraprostatic injection of a biodegradable sustained release formulation. By injecting the treatment substance directly into the prostate, improved treatment results are obtained with a much lower treatment substance dosage. Additionally, by incorporating the treatment substance into a biodegradable sustained release formulation, the need for frequent repetition of injections is eliminated.

The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and / or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.

Systems and methods for displaying a predicted outcome of a lung volume reduction procedure for a patient including a user interface, a processor, and programing operable on the processor for displaying a predicted outcome of the bronchoscopic lung volume reduction procedure on the user interface, wherein displaying the predicted outcome of the lung volume reduction procedure includes receiving patient data comprising volumetric images of the patient, analyzing the volumetric images to identify one or more features correlated to treatment outcome prediction, predicting an outcome for a treatment modality or treatment device using the one or more identified features, and displaying the predicted outcome on the user interface.

The present invention provides apparatus and methods for the delivery of therapeutic agents to target tissues by electromigration. The utilization of electric fields according to the methods of the invention aids in the distribution and targeting of therapeutic agents, in particular, where standard means of agent application in the target tissue is insufficient to achieve prophylactic or therapeutic results. In particular embodiments, the present invention utilizes a convective force in combination with the developed electric fields to further increase the flux of the therapeutic agent or to further improve distribution of the therapeutic agent within the target tissues.

The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and / or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiences using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.

A predictor of medical treatment outcome is developed and applied. A prognosis model is developed from literature. The model is determined by reverse engineering the literature reported quantities. A relationship of a given variable to a treatment outcome is derived from the literature. A processor may then use individual patient values for one or more variables to predict outcome. The accuracy may be increased by including a data driven model in combination with the literature driven model.

The invention provides compositions and methods for determining the increased risks for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.